CareDx Partners with HeartBrothers Foundation to Help Patients Living with Heart Failure and Heart Transplant

Rhea-AI Summary

CareDx, Inc. (Nasdaq: CDNA) announced its partnership with the HeartBrothers Foundation to host a patient education webinar on navigating heart transplantation. This event will take place on March 31, 2022, and aims to provide insights into the transplant journey through personal stories and information on non-invasive post-transplant surveillance. CareDx highlights its commitment to supporting heart failure patients and promotes its AlloMap® Heart product, utilized by over 90% of heart transplant centers. The partnership underscores CareDx's dedication to enhancing patient education and support in the transplant community.

Positive

• Partnership with HeartBrothers Foundation enhances community support for heart failure patients.
• Educational webinar scheduled for March 31, 2022, to provide valuable insights for patients.
• AlloMap® Heart used by over 90% of heart transplant centers, indicating strong market presence.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is partnering with the HeartBrothers Foundation as a corporate member and also hosting a patient education webinar together. HeartBrothers is a non-profit organization dedicated to helping patients with heart failure, including those receiving heart transplants, navigate their heart-related challenges.

On Thursday, March 31, CareDx and the HeartBrothers Foundation will co-host an educational webinar offering patients tips and tools for navigating the transplant journey, including insights from the personal stories of transplant recipients and their care partners, and information about non-invasive post-transplant surveillance.

“CareDx is proud to be a longstanding corporate member of the HeartBrothers Foundation, which provides important educational, financial, and emotional support for patients and families battling the devastating effects of heart failure, as well as those who have received a transplant,” said Reg Seeto, CEO and President of CareDx. “From offering patient education webinars to housing for those economically disadvantaged and more, this group is a valuable resource for patients when they are most in need.”

“Our important work wouldn’t be possible without the support of companies like CareDx, which was our first corporate member and a steadfast supporter since 2015,” said Patrick Sullivan, a heart failure survivor and transplant recipient who is co-founder of the HeartBrothers Foundation. “We are particularly proud of what we achieved in 2021, including the launch of our HeartBrothers Patient Support Group, Heart Failure Awareness Campaign, and opening of HeartBrothers House, and are looking forward to another productive year thanks to the contributions of our corporate members.”

Webinar Details: Thursday, March 31, 2022, 5:30pm-6:30pm ET / 2:30pm-3:30pm PT. Presenters include Jesse Arnold, two-time lung transplant recipient; Lillian Beretta, founder of the Joe Beretta Foundation in honor of her husband; Ebert Mahon, kidney transplant recipient; and Patrick Sullivan, co-founder of the HeartBrothers Foundation and heart transplant recipient. To register for the event or to receive a link to the recorded session if unable to attend, go here.

The Centers for Disease Control and Prevention (CDC) estimate that there are nearly 6.2 million adults in the United States living with heart failure.¹ In 2021, UNOS estimates that there were 3,817 heart transplants performed.² One out of two newly transplanted heart patients and more than 90% of the nation’s heart transplant centers use CareDx’s AlloMap^® Heart for heart transplant surveillance.³ CareDx’s HeartCare offering, which includes AlloMap Heart and AlloSure^® Heart, has an attachment rate of over 90%, reflecting the clinical utility of multimodality surveillance.

About HeartBrothers Foundation
Founded in 2014, the HeartBrothers Foundation is a 501(c)3 non-profit foundation dedicated to helping heart failure patients and their families navigate the complicated financial world of Heart Failure (HF), Ventricular Assist Devices (VADs) and Heart Transplantation. It is its sole mission to bring resources together to help heart failure patients and their loved ones survive a life with heart failure and all its challenges. For more information, please visit: www.HeartBrothers.org

About CareDx – The Transplant Company
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward-Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s partnership with the HeartBrothers Foundation (the “Partnership”) and the educational webinar they are going to co-host (the “Webinar”). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of the Partnership and the Webinar; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed by CareDx with the SEC on February 24, 2022, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Marketing Officer
415-287-2393
sking@caredx.com

Investor Relations
Ian Cooney
(415) 722-4563
investor@CareDx.com

References:

1. The Centers for Disease Control and Prevention. https://www.cdc.gov/heartdisease/heart_failure.htm#:~:text=About%206.2%20million%20adults%20in%20the%20United%20States%20have%20heart%20failure. Accessed online March 15, 2021.
2. The U.S. Department of Health & Human Services, Organ Procurement and Transplantation Network (OPTN), https://optn.transplant.hrsa.gov/about/. Accessed online March 15, 2022.
3. CareDx data on file. March 15, 2022.
   

FAQ

What is the purpose of CareDx's partnership with the HeartBrothers Foundation?

The partnership aims to provide educational support for heart failure patients and those undergoing heart transplants.

When is the CareDx and HeartBrothers Foundation webinar scheduled?

The webinar is scheduled for March 31, 2022, from 5:30 PM to 6:30 PM ET.

What is AlloMap® Heart and its significance for CareDx?

AlloMap® Heart is a product used for heart transplant surveillance, with over 90% utilization among heart transplant centers.

How does CareDx support heart failure patients?

CareDx supports heart failure patients through educational initiatives, partnerships, and its product offerings.